for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Meridian Bioscience, Inc.

VIVO.OQ

Latest Trade

9.87USD

Change

0.34(+3.57%)

Volume

498,528

Today's Range

9.55

 - 

9.93

52 Week Range

8.96

 - 

19.82

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
9.53
Open
9.55
Volume
498,528
3M AVG Volume
5.84
Today's High
9.93
Today's Low
9.55
52 Week High
19.82
52 Week Low
8.96
Shares Out (MIL)
42.71
Market Cap (MIL)
407.04
Forward P/E
14.83
Dividend (Yield %)
5.25

Latest Developments

More

Meridian Bioscience Reports Third Quarter Adjusted Non-GAAP Earnings Per Share Of $0.16

Meridian Bioscience Says Co And Eric Rasmussen Entered Into A Separation Agreement

Meridian Bioscience Announces Closing Of Transaction To Acquire Business Of Genepoc

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Meridian Bioscience, Inc.

Meridian Bioscience, Inc. is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers. Its segments include Diagnostics and Life Science. The Diagnostics segment includes manufacturing operations in Cincinnati, and the sale and distribution of diagnostic test kits in the countries consisting of North, Central and South America; Europe, the Middle East and Africa (EMEA), and other countries outside of the Americas and EMEA. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany, and Sydney, Australia.

Industry

Medical Equipment & Supplies

Contact Info

3471 River Hills Dr

+1.513.2713700

http://www.meridianbioscience.com

Executive Leadership

David C. Phillips

Chairman of the Board, Director

John P. Kenny

Chief Executive Officer, Director

Bryan T. Baldasare

Interim Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Corporate Controller, Treasurer

Lawrence J. Baldini

Executive Vice President and President - Global Operations

James M. Anderson

Independent Director

Key Stats

3.50 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.2K

2017

0.2K

2018

0.2K

2019(E)

0.2K
EPS (USD)

2016

0.800

2017

0.670

2018

0.740

2019(E)

0.643
Price To Earnings (TTM)
16.08
Price To Sales (TTM)
2.00
Price To Book (MRQ)
2.16
Price To Cash Flow (TTM)
11.95
Total Debt To Equity (MRQ)
40.21
LT Debt To Equity (MRQ)
40.21
Return on Investment (TTM)
9.56
Return on Equity (TTM)
8.82

Latest News

FDA approves Meridian Bioscience's test for herpes in newborns

The U.S. Food and Drug Administration approved on Friday the first test - a diagnostic from Meridian Bioscience Inc - to help detect a type of herpes virus in newborns.

FDA approves Meridian Bioscience's diagnostic for herpes in newborns

The U.S. Food and Drug Administration approved on Friday a diagnostic test from Meridian Bioscience Inc as the first tool to help detect a type of herpes virus in newborns.

BRIEF-Meridian Bioscience Reports Q2 GAAP EPS Of $0.12

* MERIDIAN BIOSCIENCE REPORTS SECOND QUARTER 2018 OPERATING RESULTS, DECLARES REGULAR SECOND QUARTER CASH DIVIDEND, AND UPDATES FISCAL 2018 GUIDANCE

BRIEF-Meridian Bioscience Reports Q1 GAAP EPS Of $0.15

* MERIDIAN BIOSCIENCE REPORTS FIRST QUARTER 2018 OPERATING RESULTS, DECLARES REGULAR FIRST QUARTER CASH DIVIDEND, AND REAFFIRMS FISCAL 2018 GUIDANCE

BRIEF-Co-Diagnostics Announces Sale Of Molecular Diagnostic Tests

* CO-DIAGNOSTICS, INC. ANNOUNCES SALE OF MOLECULAR DIAGNOSTIC TESTS, INCLUDING ZIKA VIRUS, TO MAJOR CARIBBEAN LABORATORY Source text for Eikon: Further company coverage:

BRIEF-Meridian Bioscience Files For Mixed Shelf Of Up To $100 Million

* MERIDIAN BIOSCIENCE INC FILES FOR MIXED SHELF OF UP TO $100 MILLION - SEC FILING Source text: (http://bit.ly/2k7rdVf) Further company coverage:

BRIEF-Co-Diagnostics Inc says qtrly loss per share $‍0.33​

* Co-Diagnostics, Inc. Reports Q3 financial results and updates corporate developments

FDA warns Meridian of violations for lead-testing devices

(This Oct. 23 story corrects paragraph 4 to say warning letter, instead of form 483)

BRIEF-Meridian Bioscience says FDA issued warning letter related to matters at Magellan Diagnostics subsidiary​

* Meridian Bioscience Inc - announced that FDA has issued a warning letter related to matters at its Magellan Diagnostics subsidiary

FDA warns Meridian of violations for lead-testing devices

The U.S. Food and Drug Administration said on Monday it issued a warning letter to Meridian Bioscience Inc's unit for several federal law violations after inspecting its facility that makes lead-testing devices.

BRIEF-Meridian bioscience comments on preliminary fiscal 2017 operating results

* Meridian Bioscience Inc comments on preliminary fiscal 2017 operating results and provides fiscal 2018 revenue and earnings guidance

BRIEF-MERIDIAN BIOSCIENCE APPOINTS JACK KENNY AS CEO

* MERIDIAN BIOSCIENCE, INC. APPOINTS JACK KENNY AS CHIEF EXECUTIVE OFFICER

BRIEF-Meridian Bioscience introduces expansion of its ImmunoCard STAT! product line

* Meridian Bioscience Inc- Announced expansion of its ImmunoCard Stat! product line with addition of ImmunoCard Stat! FLU A&B Source text for Eikon: Further company coverage:

BRIEF-Meridian Bioscience Q3 gaap earnings per share $0.01

* Meridian Bioscience reports third fiscal quarter 2017 operating results, including non-cash goodwill impairment charge, declares regular cash dividend, and reaffirms fiscal 2017 guidance excluding the effect of goodwill impairment charge

BRIEF-Co-Diagnostics Inc announces joint venture in India

* Co-Diagnostics Inc - once deal completed, cosara will have exclusive indian manufacturing rights for co-diagnostics products

FDA raises concerns about Meridian's plant that makes lead tests

The U.S. health regulator on Thursday raised concerns about Meridian Bioscience Inc's facility that manufactures lead testing devices, nearly two months after the regulator warned that the tests may underestimate lead levels in blood.

BRIEF-Meridian Bioscience comments on FDA statement concerning inspection of Magellan diagnostics

* Meridian Bioscience Inc- Consistent with FDA policy, Magellan will promptly submit responses to form FDA-483 for agency's consideration

FDA raises fresh concerns over Meridian's lead testing device

The U.S. Food and Drug Administration on Thursday raised concerns about Meridian Bioscience Inc's facility that manufactures its testing device nearly two months after the regulator warned the tests underestimate lead levels in blood.

BRIEF-Co-Diagnostics sees IPO of 1.3 mln common shares to be priced between $6.35-$6.75/Share

* Co-Diagnostics Inc sees IPO of 1.3 million shares of common stock to be priced between $6.35 and $6.75 per share - sec filing Source text : http://bit.ly/2tb5xtJ Further company coverage:

BRIEF-Meridian Bioscience comments on recent FDA posting related to Magellan Diagnostics

* Meridian Bioscience comments on recent fda posting related to Magellan Diagnostics

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up